Cargando…

Co-occurring psychiatric disorders and disparities in buprenorphine utilization in opioid use disorder: An analysis of insurance claims

BACKGROUND: As the overdose crisis continues in the U.S. and Canada, opioid use disorder (OUD) treatment outcomes for people with co-occurring psychiatric disorders are not well characterized. Our objective was to examine the influence of co-occurring psychiatric disorders on buprenorphine initiatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Kevin Y, Huang, Vivien, Williams, Arthur Robin, Martin, Caitlin E, Bazazi, Alexander R., Grucza, Richard A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Full Length Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630609/ https://www.ncbi.nlm.nih.gov/pubmed/38023343 http://dx.doi.org/10.1016/j.dadr.2023.100195

Ejemplares similares

Psychiatric comorbidities and their treatment predict buprenorphine continuation among postpartum people with opioid use disorder
por: Shadowen, Hannah, et al.
Publicado: (2022)

Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder
por: Reed, Megan K, et al.
Publicado: (2022)

Prescription stimulant use during long-term opioid therapy and risk for opioid use disorder
por: Scherrer, Jeffrey F., et al.
Publicado: (2022)

Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk
por: Tardelli, Vitor, et al.
Publicado: (2023)

Association of chronic non-cancer pain status and buprenorphine treatment retention among individuals with opioid use disorder: Results from electronic health record data
por: John, William S., et al.
Publicado: (2022)

Differences in medicaid expansion effects on buprenorphine treatment utilization by county rurality and income: A pharmacy data claims analysis from 2009–2018
por: Golan, Olivia K., et al.
Publicado: (2023)

Receipt and duration of buprenorphine treatment during pregnancy and postpartum periods in a national privately-insured cohort
por: Wang, Xi, et al.
Publicado: (2023)

Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use
por: Xu, Kevin Y., et al.
Publicado: (2022)

An observational study on the use of long acting buprenorphine (Sublocade) and a Tamper resistant PICC for Outpatient IV antibiotic administration in Patients with serious infections and Opioid Use Disorder; The STOP OUD project
por: Pineo, Thomas, et al.
Publicado: (2021)

Buprenorphine involvement in opioid overdose deaths: A retrospective analysis of postmortem toxicology in Marion County, Indiana, 2015-2021
por: del Pozo, Brandon, et al.
Publicado: (2023)

Sex specific effects of buprenorphine on behavior, astrocytic opioid receptor expression and neuroinflammation after pediatric traumatic brain injury in mice
por: Hamood, Yesmine, et al.
Publicado: (2022)

Demographic and psychiatric correlates of compulsive sexual behaviors in gambling disorder
por: Cowie, Megan E., et al.
Publicado: (2019)

Under-representation of key demographic groups in opioid use disorder trials
por: Rudolph, Kara E., et al.
Publicado: (2022)

Associations among the opioid receptor gene (OPRM1) A118G polymorphism, psychiatric symptoms, and quantitative EEG in Korean males with gambling disorder: A pilot study
por: Kim, Kyoung Min, et al.
Publicado: (2019)

Inflammation subtypes in psychosis and their relationships with genetic risk for psychiatric and cardiometabolic disorders
por: Zhang, Lusi, et al.
Publicado: (2022)

Emergency-department initiated buprenorphine: Impact on quality of life
por: Carroll, Caleb, et al.
Publicado: (2023)

The introduction of a novel formulation of buprenorphine into organized health systems()()
por: Mullen, William, et al.
Publicado: (2022)

Negative attitudes about medications for opioid use disorder among criminal legal staff
por: Moore, Kelly E., et al.
Publicado: (2022)

Examining the relationship of concurrent obesity and tobacco use disorder on the development of substance use disorders and psychiatric conditions: Findings from the NESARC-III
por: Fields, L.J., et al.
Publicado: (2023)

Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States
por: Sun, Tianyu, et al.
Publicado: (2022)

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
por: De Aquino, Joao P., et al.
Publicado: (2021)

The association between medication for opioid use disorder and employment outcomes in the U.S.: The relevance of race and ethnicity
por: Hoang, Bai Linh, et al.
Publicado: (2022)

Critical access medication for opioid use disorder (MOUD) treatment facilities in the continental United States
por: Pollack, Harold A., et al.
Publicado: (2022)

Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use
por: Winstanley, Erin L., et al.
Publicado: (2022)

Disparities in opioid treatment access and retention among women based on pregnancy status from 2006 to 2017
por: Khachikian, Tenie, et al.
Publicado: (2022)

Examining the daily relationship between guilt, shame, and substance use among veterans with psychiatric disorders
por: Aurora, Pallavi, et al.
Publicado: (2023)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Treatment setting among individuals with opioid use and criminal legal involvement, housing instability, or Medicaid insurance, 2015-2021
por: Shearer, Riley D., et al.
Publicado: (2023)

Residential treatment and medication treatment for opioid use disorder: The role of state Medicaid innovations in advancing the field
por: O'Brien, Peggy L., et al.
Publicado: (2022)

Specific polysubstance use patterns predict relapse among patients entering opioid use disorder treatment
por: Pan, Yue, et al.
Publicado: (2022)

A qualitative exploration of the eight dimensions of wellness in opioid use disorder recovery during the postpartum period
por: Mallahan, Stephanie, et al.
Publicado: (2023)

The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV
por: Parchinski, Kaley, et al.
Publicado: (2023)

Pain interference, gambling problem severity, and psychiatric disorders among a nationally representative sample of adults
por: Barry, Declan T., et al.
Publicado: (2013)

Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder
por: Ronquest, Naoko A, et al.
Publicado: (2018)

Opioid agonist treatment initiation and linkage for hospitalized patients seen by a substance use disorder consultation service
por: Nordeck, Courtney D., et al.
Publicado: (2022)

Peer recovery coaching for comprehensive HIV, hepatitis C, and opioid use disorder management: The CHORUS pilot study
por: Martin, Anna K., et al.
Publicado: (2023)

Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder
por: Mintz, Carrie M., et al.
Publicado: (2022)

State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements
por: Silwal, Anita, et al.
Publicado: (2023)

Internet-based CBT for patients with depressive disorders in primary and psychiatric care: Is it effective and does comorbidity affect outcome?
por: Flygare, Anna-Lena, et al.
Publicado: (2019)

Time-lagged association between counseling and/or 12-Step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorder
por: Hefner, Kathryn, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2uskmkpt5l8mlsdlqh3n4rr8s0